Autolus Therapeutics (AUTL) Stock Forecast & Price Target

Autolus Therapeutics PLC is projected to achieve significant sales growth, with estimates for FY:26 reaching $167 million, representing a year-over-year increase of approximately 220%, indicating a strong potential for acceleration beyond consensus estimates. The company's pipeline shows promising development, as evidenced by favorable guidance for Aucatzyl with expected sales of $120-135 million, reflecting around a 70% growth year-over-year. Additionally, with an estimated capital of $370 million at year-end 2025, Autolus is financially well-positioned to expand its commercial presence and capitalize on its growth potential.

Autolus Therapeutics recently provided initial estimates of $120-135 million for Aucatzyl in FY:26, which are below the company's own projected figures of $167 million, indicating a potential shortfall in expected revenue growth. Furthermore, early results from the SLDAI-2K trial, despite some promising individual reductions in disease scores, suggest that the production of CAR-T therapeutics may not meet previous forecasts. Consequently, the company's FY:26 and FY:27 revenue estimates have been revised down to $133 million and $186 million, respectively, reflecting concerns about the viability and market performance of its clinical-stage pipeline.